Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
Yahoo Finance · 1 day ago
Open | 249.12 |
High | 249.31 |
Low | 241.00 |
Mkt Cap | 30.74B |
P/E (TTM) | N/A |
Div & Yield | N/A & N/A |
Prev. Close | 247.00 |
52 Wk. Low | 141.98 |
52 Wk. High | 252.87 |
Related stocks
Biopharmaceutical company
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. Wikipedia
(USD) | Q1 2024 | Y/Y |
---|---|---|
Revenue | 494.33M | 54.80% ▲ |
Net Income | -65.94M | - |
Diluted EPS | -0.52 | - |
Quarter | EPS Estimate | EPS Actual |
---|---|---|
Q2 2024 | -$1.10 | - |
Q1 2024 | -$1.18 | -$0.52 |
Q4 2023 | -$1.32 | -$1.10 |
S&P 500^GSPC | 5,460.48-22.39 (-0.41%) |
Dow 30^DJI | 39,118.86-45.20 (-0.12%) |
Nasdaq^IXIC | 17,732.60-126.08 (-0.71%) |
12.35-34.83% | |
509.26+4.69% | |
123.80-4.64% |